Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

Two adults living in Missouri have been diagnosed with the more severe Clade I Mpox, taking the total number of cases in the US to three this year.

As per the US CDC, since November 2024, there have been 12 reported cases of clade I Mpox in the country. With the two cases in Missouri, the total tally rises to 14.

The Missouri Department of Health and Senior Services (DHSS), in a statement, said that both individuals had recent international travel to countries where Mpox is more prevalent.

Further investigation revealed that the two cases are unrelated to one another and are not believed to be connected to any locally acquired Mpox cases.

“While risk to the general public remains low, Mpox is still active,” said Dr. George Turabelidze, state epidemiologist.

“We recommend those who are at risk for Mpox infection to get vaccinated and ensure they complete the 2-dose series,” Turabelidze added.

Earlier this week, New York City reported the first case of Mpox Clade I in the US.

Last week, health authorities in Argentina announced the country's first locally acquired case of mpox clade Ib, raising concerns about the potential for community transmission in South America.

Clade 1 Outbreaks

According to the CDC, more than 53,000 clade I monkeypox cases, including more than 200 deaths, have been reported in several countries in Central and Eastern Africa since January 1, 2024.

Between March 2025 and March 2026, 30 countries have reported 37,170 confirmed cases of the deadly strain, including 165 deaths.

The majority of the cases are reported from the Democratic Republic of the Congo, Sierra Leone, and Uganda.

The CDC maintains that the risk of clade I Mpox to the general public in the US remains low, while for men who have sex with men, it is low to moderate.

What is Mpox? Why is Clade 1 more deadly?

Mpox is a disease caused by two different genetic types of the mpox virus, called Clade I and Clade II.

The Missouri health department said that Clade I is more likely to cause severe illness and death, especially in people who have a weak immune system.

The latest records also show that Clade I has a mortality rate of 1-10 percent compared to Clade II’s 1-4 percent.

Both types of the virus spread primarily through direct physical contact with a symptomatic person with Mpox or through contact with used items contaminated with the Mpox virus. It is not spread through the air.

But, statistics have shown that Clade 1 infects children more than adults.

People with Mpox are considered infectious until all their lesions have crusted over, the scabs have fallen off and a new layer of skin has formed underneath, and all the lesions on the eyes and in the body (in the mouth, throat, eyes, vagina and anus) have healed too.

Other symptoms of mpox which may develop prior to a rash can include

fever,

chills,

headache,

exhaustion,

muscle aches,

sore throat,

swollen lymph nodes.

The CDC urges rapid response measures, such as contact tracing and vaccination, to effectively stop disease spread.

Vaccination reduces the risk of getting mpox and can reduce symptoms if infected.

Semaglutide: Weight loss drug like Ozempic and Wegovy are going to go generic in countries. This means the drug, but in cheaper rates, will be available to the 40 per cent of the world's population.

Novo Nordisk that until now had the monopoly over the drug will lose patent protection in several of the world's most populous countries. Health and Me had also previously reported that the first generic version is expected to arrive in India by this weekend. Soon after, generic drugs will also become available in China, Canada, Brazil, Turkey, and South Africa.

“The availability of these drugs, which have been restricted to high-income countries to very wealthy people, will now be democratized by the generics,” said Leena Menghaney, an activist in New Delhi focused on treatment access. The new markets will open up a huge customer base for the generic weight loss drugs. In India and China, there are more than 800 million obese adults or overweight, and more than 300 million adults have diabetes.

Drugs Could Be Cheaper By 90%

The generic drugs are expected to hit the shelves of Indian markets by 21 March, and costs are expected to be lower by 90 per cent. Drug makers like Nacto Pharma and Eris Lifesciences announced to roll out the weight loss jabs over 50 per cent cheaper than the innovator's price in April. They have also introduced vials for Rs 1,300 per month, which is about 90 per cent cheaper than Ozempic.

Dr Reddy's Laboratories is also gearing up to launch its generic semglutide injection in the country in March under the brand name Obeda. Other companies like Sun Pharma and Zydus Lifesciences too are entering the rat race of launching multiple generic versions to make the treatment more affordable for patients with obesity and weight-related health risks.

Until the patent is expired, the semaglutide therapies are owned by the original company. In India, semaglutide injections like Ozempic and Wegovy are soled at a high cost that has limited accessibility to many patients.

Industry analysts, as reported by NDTV, expect that one generic semaglutide enters the market from March 21, 2026, prices could be cut roughly by 50 per cent as compared to the prices it started with. This means Wegovy which was previously sold for around Rs. 10,000 per month could fall somewhere between Rs 3,500 to Rs. 4,000 per month for starter doses.

Dr Reddy's Laboratories have positioned their generic brands competitively, and could potentially offer discounts of up to 50 to 60 per cent in early competition.

How Does Semaglutide Work?

Semaglutide works as a GLP-1 receptor agonist that mimics the GLP-1 hormone to regulate appetite and blood sugar. It slows gastric emptying and makes you feel fuller longer. It also signals the brain to reduce hunger and cravings, and triggers the pancreas to release insulin when blood sugar is high.

They work by increasing insulin release in a glucose-dependent manner, decreasing the liver's production of glucagon, and slowing down the emptying of the stomach, which helps lower blood sugar levels after a meal. They also act on the brain to suppress appetite and increase feelings of fullness, leading to reduced calorie intake.

In people with type 2 diabetes, notes Harvard Health, the body's cells are resistant to the effects of insulin and body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

With the patent on semaglutide expiring today in India, NATCO Pharma has become the first drugmaker to launch the generic version of the weight-loss drug in the country.

NATCO Pharma’s generic semaglutide injection prices start at INR 1,290 per month.

“NATCO is the first company to offer generic semaglutide in multi-dose vials with customized syringes… It is the most affordable GLP-1 currently in the Indian market as it is approximately 70 percent cheaper in cost than the pen device and 90 percent cheaper than the price of the innovator’s brand,” the Hyderabad-based company said, in a statement.

The company had received approval from the Central Drugs Standard Control Organization (CDSCO) in February 2026 to manufacture and market the drug, after a clinical comparison study.

Semaglutide works by targeting key areas of the brain involved in appetite regulation and food intake. It reduces hunger, improves satiety, and cuts down food cravings, eventually inducing weight loss.

It also improves insulin resistance and has a beneficial effect on the reduction of cardiometabolic events and risk factors.

NATCO's Semaglutide Drugs

NATCO's semaglutide drugs will be sold under brand names SEMANAT and SEMAFULL in multi-dose vial formats. It will be priced:

• INR 1,290 per month for the 2 mg/1.5 ml and 4 mg/3 ml variants,
• INR 1,750 for the 8 mg/3 ml dose.

• INR 4,000 for 2 mg/1.5ml,
• INR 4,200 for 4 mg/3 ml,
• INR 4,500 per month for 8 mg/3 ml.

In comparison, Novo Nordisk's Ozempic and Wegovy in pen devices cost INR 8,800 and INR 10,850, respectively, per month for the starting doses.

NATCO has also signed a distribution partnership with Eris Lifesciences to co-market its therapy in India.

Other Generic Versions

Sun Pharmaceutical Industries, Dr. Reddy’s Laboratories, and Zydus Lifesciences are also expected to introduce their versions of semaglutide on Saturday.

Others in the pipeline include Alkem Laboratories, Torrent Pharmaceuticals, and MSN Laboratories.

With intense competition, analysts believe around 50 branded semaglutide generics will enter the Indian market within months, BBC reported.

Calling it a potential "magic-pill moment" for India, investment bank Jefferies predicted that the semaglutide market in the country could reach $1bn domestically.

Also read: CDSCO threatens action against pharma companies for promoting GLP-1 weight-loss drugs

End Of Novo Nordisk’s Patents

In January this year, Canada became the first country to lose patent protection for semaglutide. However, the country's health regulator hasn’t approved any generics so far.

Novo Nordisk is expected to lose the patent in 10 more countries, including Brazil, China, South Africa, Turkey, and Canada, by the end of 2026.

In view of losing patent, Novo Nordisk recently cut prices for Wegovy in India. The company also launched its blockbuster brand Ozempic in December.